BRPI1009287A2 - composto de quinoxalina - Google Patents

composto de quinoxalina

Info

Publication number
BRPI1009287A2
BRPI1009287A2 BRPI1009287A BRPI1009287A BRPI1009287A2 BR PI1009287 A2 BRPI1009287 A2 BR PI1009287A2 BR PI1009287 A BRPI1009287 A BR PI1009287A BR PI1009287 A BRPI1009287 A BR PI1009287A BR PI1009287 A2 BRPI1009287 A2 BR PI1009287A2
Authority
BR
Brazil
Prior art keywords
quinoxaline compound
quinoxaline
compound
Prior art date
Application number
BRPI1009287A
Other languages
English (en)
Inventor
Kubota Hideki
Azami Hidenori
Yamamoto Hirofumi
Kaizawa Hiroyuki
Tsuchiya Kazuyuki
Sugita Mari
Seo Ryushi
Yamamoto Satoshi
Nomura Takaho
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI1009287A2 publication Critical patent/BRPI1009287A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI1009287A 2009-03-05 2010-03-04 composto de quinoxalina BRPI1009287A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009052577 2009-03-05
PCT/JP2010/053586 WO2010101230A1 (ja) 2009-03-05 2010-03-04 キノキサリン化合物

Publications (1)

Publication Number Publication Date
BRPI1009287A2 true BRPI1009287A2 (pt) 2019-09-24

Family

ID=42709784

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009287A BRPI1009287A2 (pt) 2009-03-05 2010-03-04 composto de quinoxalina

Country Status (16)

Country Link
US (2) US8357688B2 (pt)
EP (1) EP2404922B1 (pt)
JP (1) JP5609861B2 (pt)
KR (1) KR20110132559A (pt)
CN (1) CN102341399A (pt)
AU (1) AU2010219598A1 (pt)
BR (1) BRPI1009287A2 (pt)
CA (1) CA2754457A1 (pt)
ES (1) ES2612954T3 (pt)
IL (1) IL214918A0 (pt)
MX (1) MX2011009314A (pt)
PL (1) PL2404922T3 (pt)
PT (1) PT2404922T (pt)
RU (1) RU2011140333A (pt)
TW (1) TW201043632A (pt)
WO (1) WO2010101230A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010219598A1 (en) * 2009-03-05 2011-09-22 Astellas Pharma Inc. Quinoxaline compounds
DK2473504T3 (en) 2009-09-03 2015-03-16 Bioenergenix Heterocyclic Compounds for Inhibition of Passover
AU2011299936A1 (en) 2010-09-07 2013-03-28 Astellas Pharma Inc. Quinoxaline compound
KR101567610B1 (ko) 2010-11-04 2015-11-09 주식회사 엘지화학 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자
WO2012119046A2 (en) * 2011-03-02 2012-09-07 Bioenergenix Heterocyclic compounds for the inhibition of pask
JP6115962B2 (ja) * 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ.ベー. 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体
CN103930423B (zh) 2011-10-07 2015-09-16 卫材Rd管理有限公司 吡唑并喹啉衍生物
CN104364257B (zh) 2012-03-23 2017-03-01 纪念斯隆-凯特琳癌症中心 5‑酰基‑6,7‑二氢噻吩并[3,2‑c]吡啶类化合物对胰腺及相关癌症的治疗作用
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
JP5666755B1 (ja) * 2013-04-05 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体の塩およびその結晶
ES2654094T3 (es) 2013-04-05 2018-02-12 Eisai R&D Management Co., Ltd. Compuestos piridinilpirazoloquinolina
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
BR112019023569A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila
JP7177772B2 (ja) 2017-06-01 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
CN114560862A (zh) * 2022-03-08 2022-05-31 山东龙辰药业有限公司 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012113A1 (en) 1991-12-17 1993-06-24 The Upjohn Company 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY
JPH07503970A (ja) 1992-02-19 1995-04-27 ジ・アップジョン・カンパニー CNS活性を有する3−置換イミダゾ(1,5−a)−キノキサリン類およびキナゾリン類
DK31093D0 (pt) 1993-03-19 1993-03-19 Novo Nordisk As
WO1996008493A1 (en) 1994-09-16 1996-03-21 Novo Nordisk A/S [1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE DERIVATIVES, THEIR PREPARATION AND USE
EP0783504B1 (en) 1994-09-16 2000-03-15 Novo Nordisk A/S [1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE DERIVATIVES, THEIR PREPARATION AND USE AS ANTAGONISTS OF AMPA-RECEPTORS
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
EP1613629A1 (en) 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
CN101198614B (zh) * 2005-06-14 2011-07-06 Aska制药株式会社 噻吩并嘧啶衍生物
KR101419075B1 (ko) 2006-08-08 2014-07-11 아스카 세이야쿠 가부시키가이샤 퀴나졸린 유도체
AU2007332439A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Therapeutic agent for urinary tract disease
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
AU2010219598A1 (en) * 2009-03-05 2011-09-22 Astellas Pharma Inc. Quinoxaline compounds

Also Published As

Publication number Publication date
PT2404922T (pt) 2016-12-22
RU2011140333A (ru) 2013-04-10
TW201043632A (en) 2010-12-16
JP5609861B2 (ja) 2014-10-22
EP2404922A4 (en) 2013-07-03
US8674096B2 (en) 2014-03-18
EP2404922B1 (en) 2016-11-09
ES2612954T3 (es) 2017-05-19
CA2754457A1 (en) 2010-09-10
US20130085134A1 (en) 2013-04-04
WO2010101230A1 (ja) 2010-09-10
US20110319385A1 (en) 2011-12-29
EP2404922A1 (en) 2012-01-11
JPWO2010101230A1 (ja) 2012-09-10
US8357688B2 (en) 2013-01-22
IL214918A0 (en) 2011-11-30
CN102341399A (zh) 2012-02-01
PL2404922T3 (pl) 2017-03-31
AU2010219598A1 (en) 2011-09-22
MX2011009314A (es) 2011-10-11
KR20110132559A (ko) 2011-12-08

Similar Documents

Publication Publication Date Title
CY2017026I1 (el) Τετρακυκλικη ενωση
SMT201600008B (it) Composti di piridazinone
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BRPI1006760A2 (pt) montagem
BRPI1013868A2 (pt) composto diaciletilenodiamina
PT2506716T (pt) Novos compostos tricíclicos
BRPI1005525A2 (pt) compostos de azaazuleno
BRPI1008774A2 (pt) espiroamida substituída
DE112010002949A5 (de) Kupplungstastpunkte
FI20095302A0 (fi) Luminesenssimääritysmenetelmä
BRPI1008827A2 (pt) deisobutenizador
PT2626350E (pt) Composto de ciclopropano
EP2404922A4 (en) quinoxaline
BRPI1014968A2 (pt) subalargador
UY33156A (es) Nuevos compuestos tienopirrol
BRPI1013493A2 (pt) composto de pirimidina
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
FR2947857B1 (fr) Agencement de deshuileur
BRPI0911393A2 (pt) composto de 5-hidroxipirimidina-4-carboxamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.